Behandlung der toxischen epidermalen Nekrolyse

Spornraft‐Ragaller, Petra; Theilen, Hermann; Gottschlich, G. S.; Ragaller, M.

doi:10.1007/s00105-006-1104-0

Cited by 14 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, it appeared to overestimate the number of deaths for patients with a score of 4 or 5, whereas it was underestimated for TEN patients. This result could confirm problems seen by 22,24 However, patient groups were small, thus making interpretation difficult. Score values of 5 or more points are usually less frequent and therefore were often summarized to a single group in past analyses.…”

Section: Discussionsupporting

confidence: 61%

Evaluation of SCORTEN on a Cohort of Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Included in the RegiSCAR Study

Sekula

Liss

Davidovici

et al. 2011

Journal of Burn Care & Research

View full text Add to dashboard Cite

The purpose of this study was to evaluate the severity-of-illness score called SCORTEN with respect to its predictive ability and by using data obtained in the RegiSCAR study, the most comprehensive European registry of patients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). For advanced comparisons, an auxiliary score (AS) was defined using data obtained in a previous study. Three hundred sixty-nine patients with SJS/TEN were included in RegiSCAR between 2003 and 2005. The data needed for calculation of SCORTEN were available for 45% of patients. The score revealed a moderate predictive ability with a slight underestimation of the total number of in-hospital deaths by 11%, an area under the receiver operating characteristic curve of 0.75, and a Brier score of 0.14. Problems could be seen by analyzing subgroups such as patients with TEN. The AS was better calibrated but discriminated worse (area under the receiver operating characteristic curve: 0.72; Brier score: 0.14). With the help of a refined score derived from SCORTEN and AS, potential for a possible improvement could be demonstrated. The authors were able to show that the predictive ability of SCORTEN is acceptable. Although improvement might be possible, SCORTEN remains the tool of choice, whereas AS might be an alternative in retrospective settings with missing laboratory data.

show abstract

Section: Discussionsupporting

confidence: 61%

Evaluation of SCORTEN on a Cohort of Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Included in the RegiSCAR Study

Sekula

Liss

Davidovici

et al. 2011

Journal of Burn Care & Research

View full text Add to dashboard Cite

show abstract

Immunoglobulins in primary antibody deficiency

et al. 2007

View full text Add to dashboard Cite

Immunoglobulin is a blood product prepared from the plasma of healthy donors. The therapeutic use of polyvalent immunoglobulins is an established therapy in primary antibody deficiencies, in idiopathic thrombocytopenic purpura (ITP) and in Guillain-Barré syndrome. However, there is an ongoing debate about the efficacy of polyvalent immunoglobulins as adjunctive therapy for sepsis. The paper presented here critically discusses the modern studies investigating the use of immunoglobulins in different diseases. The main focus is the use of immunoglobulins in patients with sepsis or septic shock.

show abstract

Evidence for the Use of Intravenous Immunoglobulins—A Review of the Literature

Kivity

Katz

Daniel³

et al. 2009

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel of immunologists and internists with experience in IVIg therapy reviewed the medical literature for published data concerning treatment with IVIg. The quality of evidence was assessed, and a summary of the available relevant literature in each disease was given. To our knowledge, this is the first all-inclusive comprehensive review, developed to assist the clinician when considering the use of IVIg in autoimmune diseases, immune deficiencies, and other conditions.

show abstract

Behandlung der toxischen epidermalen Nekrolyse

Cited by 14 publications

References 39 publications

Evaluation of SCORTEN on a Cohort of Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Included in the RegiSCAR Study

Evaluation of SCORTEN on a Cohort of Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Included in the RegiSCAR Study

Immunoglobulins in primary antibody deficiency

Evidence for the Use of Intravenous Immunoglobulins—A Review of the Literature

Contact Info

Product

Resources

About